Stock Price Quote

DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs
BSE5500.9532.65 (+0.6 %)
PREV CLOSE ( ) 5468.30
OPEN PRICE ( ) 5453.00
BID PRICE (QTY) 5498.85 (5)
OFFER PRICE (QTY) 5501.00 (30)
VOLUME 3273
TODAY'S LOW / HIGH ( )5437.05 5510.75
52 WK LOW / HIGH ( )3300 5560
NSE5503.8534.7 (+0.63 %)
PREV CLOSE( ) 5469.15
OPEN PRICE ( ) 5469.15
BID PRICE (QTY) 5503.10 (504)
OFFER PRICE (QTY) 5503.85 (22)
VOLUME 188436
TODAY'S LOW / HIGH( ) 5438.00 5513.00
52 WK LOW / HIGH ( )3295.3 5560
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 12-10 1990
Management Info
Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director
Registered Office

Address 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone 040 66966300 / 400

Email mail@divislabs.com

Website www.divislabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

05Aug Divi's Laboratories declines despite r
Divi's Laboratories is currently trading at Rs. 4831.00, down by 159.35..
03Aug Divi's Laboratories reports 21% rise i
Divi's Laboratories has reported results for first quarter ended June 30..
17Jul Divi's Laboratories informs about news
Divi's Laboratories has enclosed copies of newspaper publications regard..
20Jun Divi's Laboratories informs about disc
Divi's Laboratories has informed that the Company has sent an email comm..
04Jun Divi's Laboratories trades higher on t
Divi's Laboratories is currently trading at Rs. 4347.10, up by 26.40 poi..

Financials

in Millions
QTR Jun 24 ANNUAL 24
Net Profit430015760
Gross Profit 6030 21320
Operating Profit 700025110
Net Sales 2063076650

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  28120.05 (1.17%)
M.Cap ( in Cr)59399.87
Ajanta Pharma (BSE)
peergroup  3188.10 (2.08%)
M.Cap ( in Cr)39905.04
Suven Pharma (BSE)
peergroup  1200.00 (4.81%)
M.Cap ( in Cr)31336.95
Alkem Laboratories (BSE)
peergroup  6139.80 (0.79%)
M.Cap ( in Cr)73233.56
Concord Biotech (BSE)
peergroup  2222.45 (1.70%)
M.Cap ( in Cr)23277.11

Shareholding Pattern

FI/BANKS/INSURANCE 8.03%
PROMOTERS 51.9%
MUTUAL FUNDS/UTI 13.1%
NON-INSTITUTION 10.18%
GOVERNMENT 0%
FII 0%

About Divi's Laboratories Ltd.

Divi's Laboratories Ltd. was incorporated in the year 1990. Its today's share price is 5500.95. Its current market capitalisation stands at Rs 145689.16 Cr. In the latest quarter, company has reported Gross Sales of Rs. 77110 Cr and Total Income of Rs.80020 Cr. The company's management includes S Devendra Rao, S Ganapaty, Sunaina Singh, Rajendra Kumar Premchand, K V Chowdary, KVK Seshavataram, Ramesh BV Nimmagadda, Nilima Prasad Divi, Kiran S Divi, N V Ramana, Murali K Divi, M Satish Choudhury.

It is listed on the BSE with a BSE Code of 532488 , NSE with an NSE Symbol of DIVISLAB and ISIN of INE361B01024. It's Registered office is at 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,GachibowliHyderabad-500032, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Price Waterhouse Chartered Accountants LLP, PVRK Nageswara Rao & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.